[1]刘飞△ 史晓林 吴连国 刘康.唑来膦酸治疗骨质疏松性股骨粗隆间骨折的临床研究[J].中国中医骨伤科杂志,2015,23(09):19-21.
　LIU Fei SHI Xiaolin WU Lianguo LIU Kang.Clinical Study of Zoledronic Acid in the Treatment of Osteoporotic Intertrochanteric Fractures[J].Chinese Journal of Traditional Medical Traumatology & Orthopedics,2015,23(09):19-21.
点击复制

唑来膦酸治疗骨质疏松性股骨粗隆间骨折的临床研究
分享到：

《中国中医骨伤科杂志》[ISSN:1005-0205/CN:42-1340/R]

卷:
第23卷
期数:
2015年09期
页码:
19-21
栏目:
临床研究
出版日期:
2015-09-15

文章信息/Info

Title:
Clinical Study of Zoledronic Acid in the Treatment of Osteoporotic Intertrochanteric Fractures
文章编号:
1005-0205(2015)09-0019-03
作者:
刘飞1△ 史晓林1 吴连国1 刘康1
1.浙江中医药大学附属第二医院骨科(杭州,310005)
△.通信作者 E-mail:liufei0504@163.com
Author(s):
LIU Fei1 SHI Xiaolin1 WU Lianguo1 LIU Kang1
1.Department of Orthopedics,the Second Affiliated Hospital of Zhejiang University of Traditional Chinese Medicine, Hangzhou 310005,China.
关键词:
唑来磷酸;  骨质疏松;  髋部骨折
Keywords:
zoledronic acid;  osteoporosis;  hip fracture
分类号:
R683.42
文献标志码:
A
摘要:
目的:比较唑来膦酸与基础用药对骨质疏松股骨粗隆间骨折患者的疗效。方法:91例骨质疏松性股骨粗隆间骨折随机分成2组。唑来膦酸组为治疗组,术后1周内给予唑来膦酸注射液静滴1次,同时口服钙尔奇D和骨化三醇。基础用药组为对照组,口服钙尔奇D 和骨化三醇。采用Harris评分及视觉模拟评分(VAS评分)评价两组患者髋部疼痛及功能恢复情况,并比较术前及术后1年两组患者的骨密度值、骨折愈合时间和再次骨折发生率。结果:唑来膦酸组与基础用药组患者Harris评分、VAS评分、骨折愈合时间差异无统计学意义(P>0.05)。术后1年两组骨密度和再次骨折发生率差异有统计学意义(P<0.05)。结论:唑来膦酸注射液能够有效提高骨质疏松性股骨粗隆间骨折患者术后骨密度,降低再骨折发生率。
Abstract:
Objective: To compare the efficacy of zoledronic acid and basic medication in the treatment of osteoporotic intertrochanteric fractures.Methods:91 patients with osteoporotic intertrochanteric fractures were randomly divided into zoledronic acid group(the treatment group)and basic treatment group(the control group).The treatment group was given zoledronic acidintravenous injection one postoperative within a week, while caltrate D and calcitriol in oral. The control group was given caltrate D and calcitriol orally. Harris score and visual analogue scale(VAS score)was used to evaluate the hip pain and functional recovery of two groups. The bone mineral density(BMD)preoperative and a year postoperative, fracture healing time and the re-fracture rate were compared in all patients. Results: The Harris score, VAS score and fracture healing time show no significant difference(P>0.05)between two groups. The BMD and re-fracture rate a year postoperative were significantly different between two groups.(P<0.05).Conclusion:Zoledronic acid injection can effectively improve the BMD postoperative in patients with osteoporotic intertrochanteric fracture, and reduce the incidence of re-fracture.

参考文献/References:

[1] NIH Consensus Development Panel on Osteoporosis Prevention,Diagnosis and Therapy.Osteoperosis prevention diagnosis and therapy[J].JAMA,2001,285(6):785-795.
[2] 陈瑾瑜,彭永德,盛正妍.骨质疏松症治疗新选择—唑来膦酸[J].世界临床药物,2011,32(4):252-256.
[3] Lee YK,Ha YC,Choi HJ,et al.Bisphosphonate use and subsequent hip fracture in South Korea[J].Osteoporos Int,2013,24(11):2887-2892.
[4] Miller PD,Recker RR,Harris S,et al.Long-term fracture rates seen with continued ibandronate treatment:pooled analysis of DIVA and MOBILE long-term extension studies[J].Osteoporosis Int,2014,25(1):349-357.
[5] 王彦川,谢志进,石建宏,等.老年髋部骨折患者腰椎及髋部骨密度变化[J].四川医学,2014,35(10):1261-1263.
[6] 徐苓.2011版《原发性骨质疏松症临床诊疗指南》解读[J].药品评价,2012,9(7):9-12.
[7] Ghirardi A,Di Bari M,Zambon A,et al.Effectiveness of oral bisphosphonates for primary prevention of osteoporotic fractures[J].Eur J Clin Pharmacol,2014,70(9):1129-1137.
[8] Cotte FE,Fardellone P,Mercier F,et al.Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis[J].Osteoporos Int,2010,21(1):145-155.
[9] 甄东,邱冰.唑来膦酸治疗35例原发性骨质疏松症的疗效及观察[J].中国骨质疏松杂志,2012,18(2):166-168.
[10] Weycker D,Lamerato L,Schooley S,et al.Adherence with bisphosphonate therapy and change in bone mineral density among women with osteoporosis or osteopenia in clinical practice[J].Osteoporos Int,2013,24(4):1483-1489.
[11] Reid IR,Black DM,Eastell R,et al.Reduction in the risk of clinical fractures after a single dose of zoledronic acid 5 milligrams[J].J Clin Endocrinol Metab,2013,98(2):557-563.
[12] Magaziner JS,Orwig DL,Lyles KW,et al.Subgroup variations in bone mineral density response to zoledronic acid after hip fracture[J].J Bone Miner Res,2014,29(12):2545-2551.
[13] 李敬会,蔡莉莉,李德梅.唑来膦酸治疗老年骨质疏松症临床分析[J].实用老年医学,2013,27(9):777-778.
[14] Sim Iew,Ebeling PR.Treatment of osteoporosis in men with bisphosphonates:rationale and latest evidence[J]. Ther Adv Musculoskelet Dis,2013,5(5):259-267.
[15] 郑振雨,荆波,尹芸生.唑来膦酸对成骨细胞增殖及IGF-1表达的影响[J].中国医药导报,2010,35(7):20-21.
[16] 宋敏,董万涛,陈秉虎,等.V-ATPase a3转运系统影响破骨细胞、骨吸收及骨折愈合的分子机制[J].中国组织工程研究,2014,20(18):3257-3261.

备注/Memo

备注/Memo:
收稿日期:2014-12-15
基金项目:浙江省自然科学基金(LY12H27013)
浙江省医药卫生科技计划项目(2013KYA143)
更新日期/Last Update: 2015-09-15